Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Animals
Blood-Brain Barrier
/ drug effects
Brain Neoplasms
/ diagnosis
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Disease Models, Animal
Female
Gene Rearrangement
Humans
Immunohistochemistry
Lung Neoplasms
/ drug therapy
Macrocyclic Compounds
/ pharmacology
Mice
Protein Kinase Inhibitors
/ pharmacology
Protein-Tyrosine Kinases
/ genetics
Proto-Oncogene Proteins
/ genetics
Pyrazoles
/ pharmacology
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
22
08
2019
revised:
15
01
2020
accepted:
17
02
2020
pubmed:
10
4
2020
medline:
15
9
2021
entrez:
10
4
2020
Statut:
ppublish
Résumé
Although first-line crizotinib treatment leads to clinical benefit in Antitumor activity of repotrectinib was evaluated in Repotrectinib potently inhibited Repotrectinib is a novel next-generation ROS1-TKI with improved potency and selectivity against treatment-naïve and ROS1
Identifiants
pubmed: 32269053
pii: 1078-0432.CCR-19-2777
doi: 10.1158/1078-0432.CCR-19-2777
pmc: PMC10283448
mid: NIHMS1566218
doi:
Substances chimiques
Macrocyclic Compounds
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins
0
Pyrazoles
0
repotrectinib
08O3FQ4UNP
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT03093116']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3287-3295Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Sci Rep. 2019 Dec 27;9(1):19909
pubmed: 31882684
J Thorac Oncol. 2017 Nov;12(11):1611-1625
pubmed: 28818606
Cancer Discov. 2018 Jun;8(6):714-729
pubmed: 29650534
J Clin Oncol. 2017 Aug 10;35(23):2613-2618
pubmed: 28520527
Nat Rev Cancer. 2017 Oct 25;17(11):637-658
pubmed: 29068003
Lung Cancer. 2018 Oct;124:168-178
pubmed: 30268457
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
J Thorac Oncol. 2018 Nov;13(11):1717-1726
pubmed: 29981925
Nat Commun. 2019 Aug 9;10(1):3604
pubmed: 31399568
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
Mol Cancer Ther. 2016 Apr;15(4):628-39
pubmed: 26939704
Nat Rev Clin Oncol. 2017 Dec;14(12):735-748
pubmed: 28857077
J Thorac Oncol. 2018 Sep;13(9):1373-1382
pubmed: 29883837
Clin Lung Cancer. 2019 Nov;20(6):e593-e596
pubmed: 31395437
Lancet Oncol. 2016 Dec;17(12):1653-1660
pubmed: 27825636
Cancer Discov. 2018 Oct;8(10):1227-1236
pubmed: 30093503
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Ann Oncol. 2013 Sep;24(9):2364-70
pubmed: 23788756
Clin Cancer Res. 2015 May 15;21(10):2379-87
pubmed: 25688157
JCO Precis Oncol. 2017;2017:
pubmed: 29333528
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8
pubmed: 25733882
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378